Skip to main content

Table 1 Complete and ongoing MicroShunt clinical studies

From: Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: a review

Study

Clinical study of the safety and performance of the Miami InnFocus Drainage Implant to relieve glaucoma symptoms [12]

Safety and performance of the Miami InnFocus Drainage Implant (MIDI Arrow) glaucoma drainage implant [11]

Postmarket study of the InnFocus MicroShunt [10]

InnFocus MicroShunt Versus Trabeculectomy Study (IMS) [13]

 NCT number (other study ID)

NCT00772330 (INN003)

NCT01563237 (INN004)

NCT02177123 (INN007)

NCT01881425 (INN005)

 Phase

1

2

Post market

3

 Control

Single arm

Single arm

Single arm

Randomized, parallel assignment, single masked

 Center(s)

1 (Dominican Republic)

1 (France)

6 (France, the Netherlands, Spain, Switzerland)

29 (France, Italy, the Netherlands, Spain, the UK, the USA)

 Follow up (years)

5

2

2

2

 Enrolled patients

23

72

100

889 (estimated)

 Key inclusion criteria

Age: 18–85 years

IOP: ≥ 18 and ≤ 40 mmHg inadequately controlled on tolerated medical therapy

Age: 18–85 years

IOP: ≥ 18 and ≤ 35 mmHg on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery

Age: 40–85 years

IOP: ≥ 15 and ≤ 40 mmHg on maximum tolerated medical therapy

 Key exclusion criteria

Need for glaucoma surgery combined with other ocular procedures other than cataract surgery or anticipated need for

additional ocular surgery during the study

Previous incisional ophthalmic surgery (excluding uncomplicated cataract surgery), or argon laser, selective laser, or micropulse trabeculoplasty within 90 days of enrollment

Previous conjunctival incisional ophthalmic surgery, anticipated need for additional ocular surgery during the study

 Primary outcome

IOP reduction relative to baseline at 12 months

>  20% IOP reduction from baseline at 12 months without increasing the number of glaucoma medications

 Study start

October 2007

June 2011

April 2014

August 2013

 Primary completion

November 2016

December 2016

November 2017

November 2018

 Completion

January 2017

January 2017

November 2017

November 2019 (estimated)

  1. IOP = intraocular pressure